WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New DDDs

ATC codeATC level nameNew DDDUnitAdm.routeDeadline for objection to temporary codesImplementation in ATC/DDD index
A16AX19fosdenopterin63mgPFinal2026
B01AD13apadamtase alfa and cinaxadamtase alfa200UP01.02.20252026
B03XA10efepoetin alfa20mcgP01.09.20252026
C01EB22meldonium0.75gOFinal2026
C09XX01sparsentan0.4gO01.09.20252026
D11AH10lebrikizumab8.9mgPFinal2026
J01DF51aztreonam and beta-lactamase inhibitor6 1)gPFinal2026
L01AX04dacarbazine43.3mgP01.09.20252026
L01BB04cladribine6.3 2)mgP01.09.20252026
L01EB12firmonertinib80mgOFinal2026
L01EJ04momelotinib0.2gOFinal2026
L01EK04fruquintinib3.75mgOFinal2026
L01EL05 pirtobrutinib0.2gOFinal2026
L01EM06inavolisib9mgO01.09.20252026
L01EX27capivasertib0.46gO01.09.20252026
L01FA03obinutuzumab35.7mgP01.09.20252026
L01FC01daratumumab 64.3 3)mgP01.09.20252026
L01FD01trastuzumab28.6 3)mgP01.09.20252026
L01FD02pertuzumab20mgP01.09.20252026
L01FD03trastuzumab emtansine12mgP01.09.20252026
L01FD04trastuzumab deruxtecan18mgP01.09.20252026
L01FF01nivolumab17.1mgP01.09.20252026
L01FF02pembrolizumab9.5mgP01.09.20252026
L01FF03durvalumab53.6mgP01.09.20252026
L01FF04avelumab57.1mgP01.09.20252026
L01FF05atezolizumab57.1 2)mgP01.09.20252026
L01FF06cemiplimab16.7mgP01.09.20252026
L01FG02ramucirumab 40mgP01.09.20252026
L01FX04ipilimumab10mgP01.09.20252026
L01FX05brentuximab vedotin6mgP01.09.20252026
L01FX07blinatumomab18.7mcgP01.09.20252026
L01FX08elotuzumab50mgP01.09.20252026
L01XB01procarbazine0.1gO01.09.20252026
L01XG03ixazomib0.43mgO01.09.20252026
L01XJ01vismodegib0.15gO01.09.20252026
L01XJ02sonidegib0.2gO01.09.20252026
L01XK01olaparib0.6gO01.09.20252026
L01XK02niraparib0.3gO01.09.20252026
L01XK03rucaparib1.2gO01.09.20252026
L01XX05hydroxycarbamide 1.4gO01.09.20252026
L01XX27arsenic trioxide7.5mgP01.09.20252026
L01XX44aflibercept20mgP01.09.20252026
L01XX52venetoclax0.4gO01.09.20252026
L02BX04 relugolix0.12gOFinal2026
L03AC03nogapendekin alfa and inbakicept12.5mcgintravesical Final2026
L04AE03siponimod2mgOFinal2026
L04AE05etrasimod2mgOFinal2026
L04AJ07crovalimab24.3mgPFinal2026
N06BA14solriamfetol0.1gOFinal2026
1) refers to aztreonam
2) Refers to IV infusion
3) Refers to SC injection

Last updated: 2025-06-10